Viking Therapeutics ' s NASH Drug Succeeds in Midstage Trial Viking Therapeutics ' s NASH Drug Succeeds in Midstage Trial
Viking Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease, sending its shares about 6% higher in early trade.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
More News: Fatty Liver Disease (FLD) | Gastroenterology | Liver | Liver Disease | Liver Transplant | Transplant Surgery | Transplants | Urology & Nephrology